全文获取类型
收费全文 | 310701篇 |
免费 | 27321篇 |
国内免费 | 13649篇 |
专业分类
耳鼻咽喉 | 2752篇 |
儿科学 | 6717篇 |
妇产科学 | 5236篇 |
基础医学 | 48938篇 |
口腔科学 | 6246篇 |
临床医学 | 24622篇 |
内科学 | 48143篇 |
皮肤病学 | 4388篇 |
神经病学 | 28420篇 |
特种医学 | 6705篇 |
外国民族医学 | 99篇 |
外科学 | 22519篇 |
综合类 | 46693篇 |
现状与发展 | 51篇 |
一般理论 | 7篇 |
预防医学 | 14529篇 |
眼科学 | 5114篇 |
药学 | 40061篇 |
62篇 | |
中国医学 | 11314篇 |
肿瘤学 | 29055篇 |
出版年
2024年 | 265篇 |
2023年 | 4838篇 |
2022年 | 6673篇 |
2021年 | 12597篇 |
2020年 | 11006篇 |
2019年 | 9663篇 |
2018年 | 9355篇 |
2017年 | 9792篇 |
2016年 | 10071篇 |
2015年 | 11374篇 |
2014年 | 17904篇 |
2013年 | 21079篇 |
2012年 | 17813篇 |
2011年 | 20946篇 |
2010年 | 17352篇 |
2009年 | 17576篇 |
2008年 | 17672篇 |
2007年 | 17189篇 |
2006年 | 15603篇 |
2005年 | 14027篇 |
2004年 | 11943篇 |
2003年 | 10577篇 |
2002年 | 8702篇 |
2001年 | 7448篇 |
2000年 | 6265篇 |
1999年 | 5247篇 |
1998年 | 4272篇 |
1997年 | 3907篇 |
1996年 | 3290篇 |
1995年 | 3319篇 |
1994年 | 2948篇 |
1993年 | 2435篇 |
1992年 | 2109篇 |
1991年 | 1899篇 |
1990年 | 1644篇 |
1989年 | 1356篇 |
1988年 | 1175篇 |
1987年 | 1018篇 |
1986年 | 920篇 |
1985年 | 1431篇 |
1984年 | 1297篇 |
1983年 | 914篇 |
1982年 | 978篇 |
1981年 | 783篇 |
1980年 | 667篇 |
1979年 | 550篇 |
1978年 | 396篇 |
1977年 | 326篇 |
1976年 | 314篇 |
1975年 | 202篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
22.
Dan-Dan Shan Qiu-Xian Zheng Zhi Chen 《World journal of gastrointestinal oncology》2022,14(10):1892-1902
Cancer incidence and mortality are increasing globally, leading to its rising status as a leading cause of death. The Go-Ichi-Ni-San (GINS) complex plays a crucial role in DNA replication and the cell cycle. The GINS complex consists of four subunits encoded by the GINS1, GINS2, GINS3, and GINS4 genes. Recent findings have shown that GINS2 expression is upregulated in many diseases, particularly tumors. For example, increased GINS2 expression has been found in cervical cancer, gastric adenocarcinoma, glioma, non-small cell lung cancer, and pancreatic cancer. It correlates with the clinicopathological characteristics of the tumors. In addition, high GINS2 expression plays a pro-carcinogenic role in tumor development by promoting tumor cell proliferation and migration, inhibiting tumor cell apoptosis, and blocking the cell cycle. This review describes the upregulation of GINS2 expression in most human tumors and the pathway of GINS2 in tumor development. GINS2 may serve as a new marker for tumor diagnosis and a new biological target for therapy. 相似文献
23.
24.
目的观察重组人表皮生长因子凝胶联合CO2点阵激光治疗烧伤及创伤后增生性瘢痕的临床效果。 方法选择2020年12月至2021年10月安徽医科大学第一附属医院烧伤与创面修复外科收治的20例增生性瘢痕患者,按照随机数字表法将患者分为联合治疗组及单纯激光治疗组,每组10例。术前均对2组患者术区进行拍照存像、消毒、擦干,局部均匀涂抹5%复方利多卡因乳膏后以无菌薄膜封闭保护60 min,擦去乳膏后再次消毒术区。术中使用CO2点阵激光治疗仪对患者瘢痕部位进行扫描,根据患者增生性瘢痕厚度选定合适的机器参数,维持机器频率300 Hz及密度5%,在20~30 J调整能量参数的大小,时间间隔1 s,保证点阵矩形完全覆盖增生瘢痕,允许2次激光形成的热损伤矩阵之间存在25%面积的重叠。术后即刻冷敷创面60 min,冷敷结束至术后1周,单纯激光治疗组不外用任何药物,联合治疗组术区加用重组人表皮生长因子凝胶外用,3次/d。术后3 d治疗部位不碰水,若出现感染情况,可以加用抗生素软膏,点状损伤创面外痂皮未掉落完全时禁止擦洗创面,禁止直接剥除痂皮,禁止术区涂抹化妆品等,避免接受阳光直射。于第1次激光治疗后2个月进行第2次激光治疗,以2次CO2点阵激光治疗为1个疗程,1个疗程治疗后间隔2个月待术区稳定后行疗效判断,计算2组患者治疗的总有效率;根据温哥华瘢痕量表(VSS)与患者与观察者瘢痕评估量表(POSAS)对患者治疗前、第1次激光治疗后2个月、第2次激光治疗后2个月瘢痕的各项指标进行评分。数据比较采用重复测量方差分析和χ2检验。 结果(1)治疗1个疗程后2个月,单纯激光治疗组与联合治疗组患者治疗的总有效率分别为80%(8/10)、90%(9/10),2组间比较差异无统计学意义(χ2=2.40,P=0.49)。(2)对2组VSS评分的各项指标进行比较,其中疼痛、瘙痒、柔软度及厚度评分的组内及组间各时相点比较,差异均无统计学意义(P>0.05)。治疗前、第1次激光治疗后2个月及第2次激光治疗后2个月,单纯激光治疗组VSS评分中色泽评分分别为(1.9±0.7)、(1.9±0.1)、(1.8±1.0)分,联合治疗组分别为(2.9±0.7)、(2.8±0.6)、(1.9±0.7)分,2组在不同时相点组内比较,差异有统计学意义(F= 26.143,P<0.05);2组组间不同时相点比较,差异有统计学意义(F=6.753,P=0.018)。治疗前、第1次激光治疗后2个月及第2次激光治疗后2个月,单纯激光治疗组VSS评分中血管分布评分分别为(1.8±1.0)、(1.7±0.7)、(1.5±1.0)分,联合治疗组分别为(2.6±0.5)、(2.5±0.5)、(1.7±0.8)分,2组在不同时相点组内比较,差异有统计学意义(F=17.603,P<0.05),2组组间不同时相点比较,差异无统计学意义(F= 2.538,P=0.129)。(3)对2组POSAS评分的各项指标进行比较,其中厚度、粗糙度、柔软度和表面积评分的组内及组间各时相点比较,差异均无统计学意义(P>0.05)。治疗前、第1次激光治疗后2个月及第2次激光治疗后2个月,单纯激光治疗组POSAS评分中色泽评分分别为(4.9±2.6)、(4.1±0.8)、(3.5±2.0)分,联合治疗组分别为(7.6±1.1)、(6.8±1.4)、(5.4±1.8)分,2组在不同时相点组内比较,差异有统计学意义(F= 26.509,P<0.05),2组组间不同时相点比较,差异有统计学意义(F= 8.973,P=0.008)。治疗前、第1次激光治疗后2个月及第2次激光治疗后2个月,单纯激光治疗组POSAS评分中血管分布评分分别为(4.4±2.1)、(3.9±0.9)、(3.5±1.6)分,联合治疗组分别为(6.3±1.1)、(5.7±2.0)、(4.5±1.6)分,2组在不同时相点组内比较,差异有统计学意义(F= 20.118,P<0.05),2组组间不同时相点比较,差异有统计学意义(F= 5.744,P=0.028)。 结论重组人表皮生长因子凝胶联合CO2点阵激光及单独使用CO2点阵激光治疗增生性瘢痕均效果明确,但联合使用重组人表皮生长因子凝胶能有效促进创面愈合、改善瘢痕组织血管分布和减少局部色素沉着。 相似文献
25.
26.
27.
探究p53 基因突变与骨髓增殖性肿瘤(MPN)临床特征及预后的关系。方法 选取2017年1月~2020年1月本院收治的MPN患者126例,二代测序法检测患者p53 基因突变情况。对患者进行随访,统计患者总生存(OS)时间和累计生存率;分析p53 基因突变对患者临床特征、预后的影响。结果 126例MPN患者中12例(9.52%)检出p53基因突变,突变主要位于4~8号外显子上,不同类型患者的p53 基因突变检出率比较差异无统计学意义(P>0.05)。p53突变组患者年龄大于p53 非突变组,WBC水平低于p53 非突变组(P<0.05),两组患者的染色体核型、IPSS预后分层比较差异无统计学意义(P>0.05);p53 非突变组患者的OS时间、累计生存率均明显高于p53突变组患者(P<0.05)。结论 MPN患者p53 基因突变发生率较高,与患者年龄、WBC水平、异常核型及IPSS预后分层相关,p53 基因突变会影响患者的预后,可作为临床筛查预后不良高风险人群的客观指标。 相似文献
28.
29.
《Health & place》2022
PurposeAccording to the social determinants of health framework, income inequality is a potential risk factor for adverse mental health. However, few studies have explored the mechanisms suspected to mediate this relationship. The current study addresses this gap through a mediation analysis to determine if social support and community engagement act as mediators linking neighbourhood income inequality to maternal anxiety and depressive symptoms within a cohort of new mothers living in the City of Calgary, Canada.MethodsData collected at three years postpartum from mothers belonging to the All Our Families (AOF) cohort were used in the current study. Maternal data were collected between 2012 and 2015 and linked to neighbourhood socioeconomic data from the 2006 Canadian Census. Income inequality was measured using Gini coefficients derived from 2006 after-tax census data. Generalized structural equation models were used to quantify the associations between income inequality and mental health symptoms, and to assess the potential direct and indirect mediating effects of maternal social support and community engagement.ResultsIncome inequality was not significantly associated with higher depressive symptoms (β = 0.32, 95%CI = −0.067, 0.70), anxiety symptoms (β = 0.11, 95%CI = −0.39, 0.60), or lower social support. Income inequality was not associated with community engagement. For the depression models, higher social support was significantly associated with lower depressive symptoms (β = −0.13, 95%CI = −0.15, −0.097), while community engagement was not significantly associated with depressive symptoms (β = 0.059, 95%CI = −0.15, 0.27). Similarly, for the anxiety models, lower anxiety symptoms were significantly associated with higher levels of social support (β = −0.17, 95%CI = −0.20, −0.13) but not with higher levels of community engagement (β = 0.14, 95%CI = −0.14, 0.41).ConclusionThe current study did not find clear evidence for social support or community engagement mediating the relationship between neighbourhood income inequality and maternal mental health. Future investigations should employ a broader longitudinal approach to capture changes in income inequality, potential mediators, and mental health symptomatology over time. 相似文献
30.
《Journal of vascular and interventional radiology : JVIR》2022,33(9):1034-1044.e29
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies. 相似文献